These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 22740727)

  • 1. After avandia: the use of antidiabetic drugs in patients with heart failure.
    Khalaf KI; Taegtmeyer H
    Tex Heart Inst J; 2012; 39(2):174-8. PubMed ID: 22740727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucose supply and insulin demand dynamics of antidiabetic agents.
    Monte SV; Schentag JJ; Adelman MH; Paladino JA
    J Diabetes Sci Technol; 2010 Mar; 4(2):365-81. PubMed ID: 20307399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
    Rosenstock J; Rood J; Cobitz A; Biswas N; Chou H; Garber A
    Diabetes Obes Metab; 2006 Nov; 8(6):650-60. PubMed ID: 17026489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A clinical trial to maintain glycemic control in youth with type 2 diabetes.
    ; Zeitler P; Hirst K; Pyle L; Linder B; Copeland K; Arslanian S; Cuttler L; Nathan DM; Tollefsen S; Wilfley D; Kaufman F
    N Engl J Med; 2012 Jun; 366(24):2247-56. PubMed ID: 22540912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Medication of the month. Rosiglitazone (Avandia)].
    Scheen AJ
    Rev Med Liege; 2002 Apr; 57(4):236-9. PubMed ID: 12073798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies.
    Varas-Lorenzo C; Margulis AV; Pladevall M; Riera-Guardia N; Calingaert B; Hazell L; Romio S; Perez-Gutthann S
    BMC Cardiovasc Disord; 2014 Sep; 14():129. PubMed ID: 25260374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher mortality rate in patients with heart failure who are taking commonly prescribed antidiabetic medications and achieve recommended levels of glycaemic control.
    Packer M
    Diabetes Obes Metab; 2018 Jul; 20(7):1766-1769. PubMed ID: 29469167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complementary mode of action of rosiglitazone and metformin in a single tablet for the treatment of diabetes mellitus type 2.
    Petersen KU
    Arzneimittelforschung; 2004; 54(1):20-30. PubMed ID: 14979605
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
    Fonseca V; Rosenstock J; Patwardhan R; Salzman A
    JAMA; 2000 Apr; 283(13):1695-702. PubMed ID: 10755495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant α-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus.
    Huang Z; Wan X; Liu J; Deng W; Chen A; Liu L; Liu J; Wei G; Li H; Fang D; Li Y
    Diabetes Technol Ther; 2013 Oct; 15(10):859-69. PubMed ID: 23991629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
    Kahn SE; Haffner SM; Heise MA; Herman WH; Holman RR; Jones NP; Kravitz BG; Lachin JM; O'Neill MC; Zinman B; Viberti G;
    N Engl J Med; 2006 Dec; 355(23):2427-43. PubMed ID: 17145742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.
    Home PD; Pocock SJ; Beck-Nielsen H; Curtis PS; Gomis R; Hanefeld M; Jones NP; Komajda M; McMurray JJ;
    Lancet; 2009 Jun; 373(9681):2125-35. PubMed ID: 19501900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosiglitazone maleate/metformin hydrochloride: a new formulation therapy for type 2 diabetes.
    Cox SL
    Drugs Today (Barc); 2004 Jul; 40(7):633-43. PubMed ID: 15510236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes.
    Jones TA; Sautter M; Van Gaal LF; Jones NP
    Diabetes Obes Metab; 2003 May; 5(3):163-70. PubMed ID: 12681023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients.
    Negro R; Mangieri T; Dazzi D; Pezzarossa A; Hassan H
    Diabetes Res Clin Pract; 2005 Oct; 70(1):20-5. PubMed ID: 16126119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
    Irons BK; Greene RS; Mazzolini TA; Edwards KL; Sleeper RB
    Pharmacotherapy; 2006 Feb; 26(2):168-81. PubMed ID: 16466323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapy with glitazones--a risk for cardiovascular disease?].
    Rottlaender D; Michels G; Erdmann E; Hoppe UC
    Dtsch Med Wochenschr; 2007 Dec; 132(49):2629-32. PubMed ID: 18050028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.